Secretory sphingomyelinase
- PMID: 11001566
- DOI: 10.1016/s0009-3084(99)00080-8
Secretory sphingomyelinase
Abstract
Several physiologic and pathophysiologic processes in which sphingomyelinases (SMases) have been implicated may involve extracellular sphingomyelin (SM) hydrolysis. A candidate enzyme for these processes is a recently discovered SMase called secretory SMase, or S-SMase. S-SMase arises from the acid sphingomyelinase (ASM) gene via differential protein trafficking of a common protein precursor; this precursor can be targeted to either lysosomes or the Golgi secretory pathway. S-SMase is activated by physiologic levels of Zn2+, although the S-SMase from endothelial cells, which secrete abundant amounts of the enzyme, is partially Zn2+-independent. S-SMase functions best at acid pH but can hydrolyze certain physiologic substrates, such as atherogenic lipoproteins, at neutral pH. In endothelial cells, the secretion of S-SMase is regulated at the level of protein trafficking by inflammatory cytokines. Current work implicates a role for S-SMase in atherogenesis, and future work will be directed at understanding the potential roles of S-SMase in other processes, such as ceramide-mediated cell-signaling and the host inflammatory response.
Similar articles
-
The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene.J Biol Chem. 1998 Jul 17;273(29):18250-9. doi: 10.1074/jbc.273.29.18250. J Biol Chem. 1998. PMID: 9660788
-
Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling.J Biol Chem. 1998 Feb 13;273(7):4081-8. doi: 10.1074/jbc.273.7.4081. J Biol Chem. 1998. PMID: 9461601
-
Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development.J Biol Chem. 1998 Jan 30;273(5):2738-46. doi: 10.1074/jbc.273.5.2738. J Biol Chem. 1998. PMID: 9446580
-
Neutral sphingomyelinase: past, present and future.Chem Phys Lipids. 1999 Nov;102(1-2):79-96. doi: 10.1016/s0009-3084(99)00077-8. Chem Phys Lipids. 1999. PMID: 11001563 Review.
-
Ceramide and sphingomyelinases in the regulation of stress responses.Chem Phys Lipids. 1999 Nov;102(1-2):141-7. doi: 10.1016/s0009-3084(99)00082-1. Chem Phys Lipids. 1999. PMID: 11001568 Review.
Cited by
-
Targeting acid sphingomyelinase with anti-angiogenic chemotherapy.Cell Signal. 2017 Jan;29:52-61. doi: 10.1016/j.cellsig.2016.09.010. Epub 2016 Oct 1. Cell Signal. 2017. PMID: 27702691 Free PMC article.
-
Pazopanib radio-sensitization of human sarcoma tumors.Oncotarget. 2018 Jan 20;9(10):9311-9324. doi: 10.18632/oncotarget.24281. eCollection 2018 Feb 6. Oncotarget. 2018. PMID: 29507692 Free PMC article.
-
Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings.Cancer Metastasis Rev. 2025 Mar 15;44(1):39. doi: 10.1007/s10555-025-10255-5. Cancer Metastasis Rev. 2025. PMID: 40088396 Free PMC article. Review.
-
Ceramide and mitochondria in ischemia/reperfusion.J Cardiovasc Pharmacol. 2009 Mar;53(3):198-208. doi: 10.1097/FJC.0b013e31819b52d5. J Cardiovasc Pharmacol. 2009. PMID: 19247196 Free PMC article. Review.
-
Role of acid sphingomyelinase-induced ceramide generation in response to radiation.Oncotarget. 2019 Jan 1;10(1):6-7. doi: 10.18632/oncotarget.26526. eCollection 2019 Jan 1. Oncotarget. 2019. PMID: 30713596 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources